Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$8.74 - $11.84 $7.77 Million - $10.5 Million
-888,980 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$8.71 - $10.72 $871,000 - $1.07 Million
100,000 Added 12.67%
888,980 $8.57 Million
Q1 2021

May 14, 2021

SELL
$9.2 - $23.86 $4.84 Million - $12.6 Million
-526,415 Reduced 40.02%
788,980 $7.8 Million
Q4 2020

Feb 12, 2021

SELL
$13.47 - $24.89 $1.89 Million - $3.48 Million
-140,000 Reduced 9.62%
1,315,395 $30.4 Million
Q3 2020

Nov 12, 2020

SELL
$12.89 - $15.89 $644,500 - $794,500
-50,000 Reduced 3.32%
1,455,395 $20.6 Million
Q2 2020

Aug 04, 2020

BUY
$8.86 - $15.69 $1.46 Million - $2.59 Million
165,000 Added 12.31%
1,505,395 $22.7 Million
Q1 2020

May 08, 2020

BUY
$6.63 - $11.16 $8.89 Million - $15 Million
1,340,395 New
1,340,395 $12.4 Million

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.75B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Fairmount Funds Management LLC Portfolio

Follow Fairmount Funds Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fairmount Funds Management LLC with notifications on news.